Valley National Advisers Inc. Acquires Shares of 1,785 Integra LifeSciences Holdings Co. (NASDAQ:IART)

Valley National Advisers Inc. bought a new position in Integra LifeSciences Holdings Co. (NASDAQ:IART) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,785 shares of the life sciences company’s stock, valued at approximately $63,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Gotham Asset Management LLC raised its position in shares of Integra LifeSciences by 8.3% during the 3rd quarter. Gotham Asset Management LLC now owns 30,091 shares of the life sciences company’s stock valued at $1,149,000 after acquiring an additional 2,302 shares during the last quarter. Quadrature Capital Ltd lifted its stake in Integra LifeSciences by 20.5% in the 3rd quarter. Quadrature Capital Ltd now owns 33,722 shares of the life sciences company’s stock valued at $1,288,000 after purchasing an additional 5,726 shares during the last quarter. Teachers Retirement System of The State of Kentucky lifted its position in Integra LifeSciences by 22.5% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 23,849 shares of the life sciences company’s stock worth $911,000 after acquiring an additional 4,384 shares during the last quarter. Vanguard Group Inc. lifted its position in Integra LifeSciences by 1.0% during the third quarter. Vanguard Group Inc. now owns 7,159,854 shares of the life sciences company’s stock worth $273,435,000 after acquiring an additional 72,294 shares during the last quarter. Finally, Gladius Capital Management LP acquired a new stake in Integra LifeSciences during the third quarter worth approximately $47,000. 84.78% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have issued reports on IART. Morgan Stanley cut their price objective on shares of Integra LifeSciences from $37.00 to $24.00 and set an “underweight” rating for the company in a research report on Tuesday, May 7th. Citigroup lifted their price target on shares of Integra LifeSciences from $24.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, May 22nd. Wells Fargo & Company downgraded shares of Integra LifeSciences from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $45.00 to $25.00 in a research report on Tuesday, May 7th. Oppenheimer downgraded shares of Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 7th. Finally, JMP Securities dropped their price target on shares of Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating for the company in a research report on Tuesday, May 7th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $33.88.

Insider Buying and Selling at Integra LifeSciences

In related news, Chairman Stuart Essig bought 52,641 shares of the firm’s stock in a transaction on Thursday, May 23rd. The shares were purchased at an average price of $28.49 per share, with a total value of $1,499,742.09. Following the completion of the purchase, the chairman now owns 487,922 shares in the company, valued at approximately $13,900,897.78. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 3.10% of the company’s stock.

Integra LifeSciences Price Performance

IART traded down $0.46 during trading on Wednesday, hitting $28.73. 833,632 shares of the stock traded hands, compared to its average volume of 1,107,109. Integra LifeSciences Holdings Co. has a twelve month low of $22.36 and a twelve month high of $46.75. The company has a market cap of $2.26 billion, a price-to-earnings ratio of 57.46, a PEG ratio of 1.05 and a beta of 1.11. The company has a debt-to-equity ratio of 1.15, a current ratio of 4.68 and a quick ratio of 3.35. The business has a 50 day moving average price of $28.59 and a 200 day moving average price of $35.37.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, meeting the consensus estimate of $0.55. Integra LifeSciences had a net margin of 2.63% and a return on equity of 14.27%. The business had revenue of $368.90 million during the quarter, compared to the consensus estimate of $361.96 million. During the same period in the previous year, the business earned $0.74 earnings per share. The company’s revenue was down 3.2% on a year-over-year basis. Equities research analysts forecast that Integra LifeSciences Holdings Co. will post 3.03 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.